Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

Seminars in Ophthalmology

Volumn 26, Issue 3, 2011, Pages 139-148

  Moshfeghi, Andrew A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Intravitreal injection

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; LOMEFLOXACIN; PEGAPTANIB; POLYMYXIN; RANIBIZUMAB; TRIMETHOPRIM; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERTERPORFIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; EXUDATIVE MACULAR DEGENERATION; EYE IRRITATION; EYE PAIN; FOLLOW UP; GRAM POSITIVE BACTERIUM; HUMAN; HYPOPYON; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOCOCCUS GORDONII; STREPTOCOCCUS SANGUINIS; UVEITIS; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957610019     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.570847     Document Type: Article

References (61)

1. Aiello LP, et al. Evolving guidelines for intravitreous injections. Retina, 2004; 24(5 Suppl):S3-19.
2. Jager RD, et al. Risks of intravitreous injection: A comprehensive review. Retina, 2004; 24(5):676-98. (Pubitemid 39391758)
3. Jonas JB. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res, 2006; 38(4):218-45. (Pubitemid 44213982)
4. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand, 2005; 83(6):645-63. (Pubitemid 41819287)
5. Jonas JB, Kamppeter B. Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty. Cornea, 2006; 25(2):240-1. (Pubitemid 43362732)
6. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res, 2005; 24(5):587-611. (Pubitemid 40949559)
7. Jonas JB, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology, 2005; 112(4):593-8. (Pubitemid 41108858)
8. Jonas JB, Kreissig I, and Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol, 2003; 136(2):384-6. (Pubitemid 36904101)
9. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol, 2001; 132(3):425-7. (Pubitemid 32768624)
10. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology, 2003; 110(8):1517-25. (Pubitemid 36962483)
11. Brown DM, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology, 2009; 116(1):57-65 e5.
12. D'Amico DJ, et al. Pegaptanib sodium for neovascular agerelated macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology, 2006; 113(6):992-1001 e6.
13. Gragoudas ES, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004; 351(27):2805-16. (Pubitemid 40051904)
14. Heier JS, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology, 2006; 113(4):633 e1-4.
15. Regillo CD, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol, 2008; 145(2):239-248.
16. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006; 355(14):1419-31. (Pubitemid 44511557)
17. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005; 36(4):331-5. (Pubitemid 41073112)
18. Schwartz SG, Flynn HW, Scott IU. Endophthalmitis after intravitreal injections. Expert Opin Pharmacother, 2009; 10(13):2119-26.
19. Michels S, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology, 2005; 112(6):1035-47. (Pubitemid 40797459)
20. Moshfeghi AA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology, 2006; 113(11):2002 e1-12.
21. Avery RL, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 2006; 113(3):363-372 e5.
22. Gregori NZ, et al. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina, 2008; 28(9): 1325-37.
23. Gregori NZ, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina, 2009; 29(7):913-25.
24. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging, 2005; 36(4):336-9. (Pubitemid 41073113)
25. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol, 2009; 20(3): 158-65.
26. Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than agerelated macular degeneration. Curr Opin Ophthalmol, 2009; 20(3):166-74.
27. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol, 2009; 54(3):372-400.
28. Brown DM, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology, 2010; 117(6):1124-1133 e1.
29. Campochiaro PA, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology, 2010; 117(6):1102-1112 e1.
30. Jeganathan VS. Anti-angiogenesis drugs in diabetic retinopathy. Curr Pharm Biotechnol, 2011;12(3):369-72.
31. Amato JE, et al. Steroid hypopyon following intravitreal triamcinolone acetonide injection in a pseudophakic patient. Ocul Immunol Inflamm, 2005; 13(2-3):245-7. (Pubitemid 41711298)
32. Chen SD, et al. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br J Ophthalmol, 2004; 88(6): 843-4. (Pubitemid 38725609)
33. Moshfeghi AA, et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol, 2004; 138(3):489-92. (Pubitemid 39208586)
34. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol, 2003; 87(8):972-4. (Pubitemid 36936293)
35. Bakri SJ et al. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol, 2008; 246(7):955-8.
36. Cunningham ET et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 2005; 112(10):1747-57.
37. Elman MJ, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 2010; 117(6):1064-1077 e35.
38. Brown DM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 2006; 355(14):1432-44. (Pubitemid 44511558)
39. Boyer DS, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology, 2009; 116(9): 1731-9.
40. Aggio FB, et al. Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye (Lond), 2007; 21(3):408-9. (Pubitemid 46358806)
41. Alkuraya HS, et al. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol, 2009; 29(5):411-3.
42. Cavalcante LL, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol, 2010; 4:519-24.
43. Chen E, et al. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging, 2009; 40(2):192-4.
44. Diago T, et al. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina, 2009; 29(5):601-5.
45. Fintak DR, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina, 2008; 28(10):1395-9.
46. Georgopoulos M, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol, 2009; 93(4):457-62.
47. Jonas JB, Spandau UH, and Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye (Lond), 2008; 22(4):590-1. (Pubitemid 351560425)
48. Klein KS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology, 2009; 116(6): p. 1225 e1.
49. Lee SH, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond), 2010; 24(2):226-32.
50. Mason JO 3rd, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina, 2008; 28(4):564-7. (Pubitemid 351589565)
51. Mezad-Koursh D, et al. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina, 2010; 30(7):1051-7.
52. Pilli S, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol, 2008; 145(5):879-82.
53. Wickremasinghe SS, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology, 2008; 115(11):1911-5.
54. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol, 2008; 246(5):779-81.
55. Bakri SJ, et al. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol, 2009; 148(1):66-9 e1.
56. Lima LH, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina, 2009; 29(9):1213-7.
57. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol, 2006; 90(11):1344-9. (Pubitemid 44702055)
58. Bakri SJ, et al. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina, 2009; 29(5):573-8.
59. Forte R, et al. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res, 2010; 45(3):129-134.
60. Yip PP, et al. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol, 2009; 93(6):754-8.
61. Stewart JM, et al. Bacterial contamination of needles used for intravitreal injections: A prospective, multicenter study. Ocul Immunol Inflamm, 2011; 19(1): 32-8.